|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Birth Weight
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors.
|
31043758 |
2019 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Body Height
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Blood Protein Measurement
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
rs188845491
|
CYP3A7;CYP3A51P;ZSCAN25;CYP3A7-CYP3A51P
|
Acute Coronary Syndrome
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
|
25935875 |
2015 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
CLL progression
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1.74; P = 0.03), all-cause mortality in lung cancer patients (HR, 1.43; P = 0.009), and CLL progression (HR, 1.62; P = 0.03).
|
26964624 |
2016 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1.74; P = 0.03), all-cause mortality in lung cancer patients (HR, 1.43; P = 0.009), and CLL progression (HR, 1.62; P = 0.03).
|
26964624 |
2016 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1.74; P = 0.03), all-cause mortality in lung cancer patients (HR, 1.43; P = 0.009), and CLL progression (HR, 1.62; P = 0.03).
|
26964624 |
2016 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1.74; P = 0.03), all-cause mortality in lung cancer patients (HR, 1.43; P = 0.009), and CLL progression (HR, 1.62; P = 0.03).
|
26964624 |
2016 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1.74; P = 0.03), all-cause mortality in lung cancer patients (HR, 1.43; P = 0.009), and CLL progression (HR, 1.62; P = 0.03).
|
26964624 |
2016 |
|
rs45446698
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping this SNP in 1,008 breast cancer, 1,128 lung cancer, and 347 CLL patients, we found that rs45446698 was associated with breast cancer mortality (HR, 1.74; P = 0.03), all-cause mortality in lung cancer patients (HR, 1.43; P = 0.009), and CLL progression (HR, 1.62; P = 0.03).
|
26964624 |
2016 |
|
rs10211
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
In the Czech population, carriers of the ancestral alleles of AGT rs699 and CYP3A7 rs10211 showed an increased risk of CRC (OR 1.26 and 1.38, respectively; two-sided p≤0.05), whereas carriers of the ancestral allele of ENPP1 rs1044498 had a decreased risk (OR 0.79; p≤0.05).
|
23036011 |
2012 |
|
rs28451617
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Respiratory Distress Syndrome
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6).
|
22445700 |
2012 |
|
rs28451617
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Respiratory Distress Syndrome, Newborn
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6).
|
22445700 |
2012 |
|
rs28451617
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Respiratory Distress Syndrome, Adult
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6).
|
22445700 |
2012 |
|
rs28451617
|
CYP3A7;ZSCAN25;CYP3A7-CYP3A51P
|
Glucocorticoid Receptor Deficiency
|
|
0.010 |
GeneticVariation |
BEFREE |
Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6).
|
22445700 |
2012 |